GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immix Biopharma Inc (NAS:IMMX) » Definitions » EV-to-EBITDA

IMMX (Immix Biopharma) EV-to-EBITDA : -2.81 (As of Jul. 12, 2025)


View and export this data going back to 2021. Start your Free Trial

What is Immix Biopharma EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Immix Biopharma's enterprise value is $60.69 Mil. Immix Biopharma's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 was $-21.62 Mil. Therefore, Immix Biopharma's EV-to-EBITDA for today is -2.81.

The historical rank and industry rank for Immix Biopharma's EV-to-EBITDA or its related term are showing as below:

IMMX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -2.81   Med: 0   Max: 0
Current: -2.81

IMMX's EV-to-EBITDA is ranked worse than
100% of 462 companies
in the Biotechnology industry
Industry Median: 10.615 vs IMMX: -2.81

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2025-07-12), Immix Biopharma's stock price is $2.65. Immix Biopharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 was $-0.700. Therefore, Immix Biopharma's PE Ratio (TTM) for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).


Immix Biopharma EV-to-EBITDA Historical Data

The historical data trend for Immix Biopharma's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immix Biopharma EV-to-EBITDA Chart

Immix Biopharma Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-EBITDA
Get a 7-Day Free Trial - -1.22 -2.24 -7.45 -1.95

Immix Biopharma Quarterly Data
Dec19 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.74 -1.56 -0.97 -1.95 -1.48

Competitive Comparison of Immix Biopharma's EV-to-EBITDA

For the Biotechnology subindustry, Immix Biopharma's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Immix Biopharma's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immix Biopharma's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Immix Biopharma's EV-to-EBITDA falls into.


;
;

Immix Biopharma EV-to-EBITDA Calculation

Immix Biopharma's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=60.685/-21.617
=-2.81

Immix Biopharma's current Enterprise Value is $60.69 Mil.
Immix Biopharma's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-21.62 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Immix Biopharma  (NAS:IMMX) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Immix Biopharma's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=2.65/-0.700
=At Loss

Immix Biopharma's share price for today is $2.65.
Immix Biopharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.700.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?


Immix Biopharma EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Immix Biopharma's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Immix Biopharma Business Description

Traded in Other Exchanges
N/A
Address
11400 West Olympic Boulevard, Suite 200, Los Angeles, CA, USA, 90064
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
Executives
Jason Hsu director 11400 WEST OLYMPIC BLVD., SUITE 200, LOS ANGELES CA 90064
Carey Ng director 11400 WEST OLYMPIC BLVD., SUITE 200, LOS ANGELES CA 90064
Ilya M Rachman director, officer: CEO and Chairman 11400 WEST OLYMPIC BLVD.,, SUITE 200, LOS ANGELES CA 90064
Gabriel S Morris director, officer: Chief Financial Officer 11400 WEST OLYMPIC BLVD.,, SUITE 200, LOS ANGELES CA 90064
Helen C. Adams director 15378 AVENUE OF SCIENCE, STE 100, SAN DIEGO CA 92128
Melissa Jane Buchan director 1920 MAIN STREET, SUITE 500, IRVINE CA 92614
Magda Marquet director ALTHEADX INC., 3550 DUNHILL STREET, SAN DIEGO CA 92121
Yekaterina Chudnovsky director, 10 percent owner C/O ELICIO THERAPEUTICS, INC., 451 D STREET, 5TH FLOOR, SUITE 501, BOSTON MA 02210
Sean Senn 10 percent owner 11400 WEST OLYMPIC BLVD., SUITE 200, LOS ANGELES CA 90064
Vladimir P Torchilin officer: Scientific Co-Founder 11400 WEST OLYMPIC BLVD.,, SUITE 200, LOS ANGELES CA 90064
Graham Ross officer: CMO & Head of Clinical Dev. 11400 WEST OLYMPIC BLVD., SUITE 200, LOS ANGELES CA 90064